Beyond the subjectively evaluated tumor-related symptoms, the Ki-67 threshold of 10%, for which SSA therapy is approved in pancreatic NET, was implemented and arbitrarily chosen in the CLARINET study, and there were retrospective data favoring this cut-off [12,13]. This evidence concerns the gene MKI67 and pancreatic neuroendocrine tumor.